Recombinant Human IL-17A
- Cat. No.：EPT053
- Price：USD $ 600.00
- Clicks：1044
Product Detail
Basic Information
| Size | 10ug |
|---|---|
| Expression Host | E.coli |
| Tag | NA |
Physical Properties
| Molecular Weight | 15.26 KDa |
|---|---|
| Apparent Molecular Weight | 16 KDa, reducing conditions |
| Form | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
Activity & Endotoxin
| Endotoxin Level | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
|---|---|
| Activity | Immobilized Human IL-17A(Cat#C021) at 2μg/ml (100 μl/well) can bind Anti-Human IL-17A mAb(Cat#NC012).The ED50 of Anti-Human IL-17A mAb(Cat#NC012) is 0.185 ug/ml. |
Storage & Shipping
| Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
|---|---|
| Storage | Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| Shipping Condition | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
Detailed Description
| Background | Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation. |
|---|
Related Products: